PACB
Pacific Biosciences of California, Inc. Healthcare - Medical Devices Investor Relations →
Pacific Biosciences of California, Inc. (PACB) closed at $1.40 as of 2026-06-19, trading 70.8% below its 200-week moving average of $4.79. This places PACB in the extreme value zone. The stock moved further from the line this week, up from -72.8% last week. The 14-week RSI sits at 52, indicating neutral momentum.
Trading volume is running at 0.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.92 ratio) is neutral — neither side is clearly dominating.
Over the past 768 weeks of data, PACB has crossed below its 200-week moving average 7 times. On average, these episodes lasted 76 weeks. Historically, investors who bought PACB at the start of these episodes saw an average one-year return of +6.1%.
With a market cap of $435 million, PACB is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -273.6%. The stock trades at 175.0x book value.
Share count has increased 33.3% over three years, indicating dilution.
Over the past 14.8 years, a hypothetical investment of $100 in PACB would have grown to $37, compared to $771 for the S&P 500. PACB has returned -6.5% annualized vs 14.8% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: PACB vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After PACB Crosses Below the Line?
Across 7 historical episodes, buying PACB when it crossed below its 200-week moving average produced an average return of -3.1% after 12 months (median +7.0%), compared to +11.4% for the S&P 500 over the same periods. 57% of those episodes were profitable after one year. After 24 months, the average return was +105.3% vs +27.7% for the index.
Each line shows $100 invested at the moment PACB crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. PACB currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from PACB's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
PACB has crossed below its 200-week MA 7 times with an average 1-year return of +6.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 2011 | Jan 2014 | 119 | 82.7% | -38.7% | -53.3% |
| Mar 2014 | Jun 2014 | 11 | 23.6% | +15.5% | -71.1% |
| Jul 2014 | Oct 2014 | 13 | 20.4% | +1.9% | -73.5% |
| Sep 2015 | Sep 2015 | 1 | 4.2% | +128.3% | -65.0% |
| Dec 2016 | Oct 2018 | 98 | 66.6% | -32.7% | -64.6% |
| Jul 2019 | Aug 2020 | 57 | 49.2% | -37.4% | -76.4% |
| Jan 2022 | Ongoing | 231+ | 90.8% | Ongoing | -86.1% |
| Average | 76 | — | +6.1% | — |
Frequently Asked Questions
Is PACB below its 200-week moving average?
Yes. As of 2026-06-19, Pacific Biosciences of California, Inc. (PACB) is trading 70.8% below its 200-week moving average of $4.79. The current price is $1.40.
What is PACB's 200-week moving average price?
Pacific Biosciences of California, Inc.'s 200-week moving average is $4.79 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when PACB drops below its 200-week moving average?
PACB has crossed below its 200-week moving average 7 times in our data. On average, buying at that moment produced a one-year return of +6.1%. These dips have historically been decent entry points. These episodes lasted 76 weeks on average.
Is PACB a good value right now?
Here's what our data says about PACB as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 52. Free cash flow is currently negative. Return on equity is -273.6%. Price-to-book is 175.0x. This is not a buy or sell recommendation — always do your own research.
How does PACB compare to the S&P 500?
Over the past 14.8 years, $100 invested in PACB would have grown to $37, compared to $771 for the S&P 500. That's -6.5% annualized vs 14.8% for the index. PACB has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19